Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...
Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...
Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate ...
Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in Pediatric Dermatology.
A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...
Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...
Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.
The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...
Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing ...
Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results